Immunogenicity and Safety of ChimeriVax Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2014
At a glance
- Drugs CYD TDV (Primary) ; Pneumococcal vaccines
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 29 Aug 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.